SpringWorks Therapeutics Total Assets 2019-2021 | SWTX

SpringWorks Therapeutics total assets from 2019 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
SpringWorks Therapeutics Annual Total Assets
(Millions of US $)
2020 $576
2019 $335
2018 $48
SpringWorks Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $495
2021-06-30 $520
2021-03-31 $555
2020-12-31 $576
2020-09-30 $286
2020-06-30 $301
2020-03-31 $317
2019-12-31 $335
2019-09-30 $348
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.077B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69